Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced new data from the TACTI-002 Phase II trial focusing on 2nd line non-small cell lung cancer (NSCLC) patients who are refractory to anti-PD-(L)1 therapy. The trial included 36 patients showing promising results with an Overall Response Rate (ORR) of 8.3% and a 33% Disease Control Rate (DCR). Additionally, 83% of patients experienced tumor growth deceleration or shrinkage. Final safety and efficacy data, including Overall Survival (OS) metrics, will be presented at the European Lung Cancer Congress (ELCC) 2023 in Copenhagen from March 29 to April 1.

Positive

• 83% of patients showed tumor growth deceleration or shrinkage.
• Overall Response Rate (ORR) of 8.3% indicates potential efficacy.
• Disease Control Rate (DCR) of 33% suggests durable responses.

Negative

• The Overall Response Rate (ORR) of 8.3% may be considered low in the context of competitive therapies.
• Patient population consisted of individuals who had already shown resistance to standard treatments.

Media Release

• 2^nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance
• 83% of patients that were studied for Tumor Growth Kinetics showed deceleration (50%) in tumour growth or shrinkage (33%) of target lesions
• Overall Response Rate (ORR) of 8.3% and Disease Control Rate (DCR) of 33% and responses were confirmed and durable with patients on study 19+ months
• Important additional final data on safety and efficacy including Overall Survival (OS) from Part B of TACTI-002 will be presented in a Mini Oral presentation at ELCC 2023

SYDNEY, AUSTRALIA, March 23, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that new data evaluating eftilagimod alpha in combination with pembrolizumab from Part B of the TACTI-002 Phase II trial in 2nd line PD-X refractory non-small cell lung cancer (NSCLC) patients has been accepted for a Mini Oral presentation at ESMO’s European Lung Cancer Congress (ELCC) 2023 taking place in Copenhagen, Denmark and virtually from 29 March to 1 April 2023.

The PD-X refractory, NSCLC patients in Part B of the TACTI-002 Phase II trial represent a difficult-to-treat patient population. All enrolled patients (N=36) had confirmed progression (i.e., two consecutive scans) after standard of care 1st line treatment with anti-PD-X therapy including a majority that received anti-PD-X therapy and chemotherapy. Additionally, most patients had low or negative PD-L1 expression.

TACTI-002 (Part B) Abstract (#11MO)
Title: Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors
Presentation session: Mini Oral
Presenter: Margarita Majem, MD, PhD, Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau
Lecture Time: 31 March 2023, 08:25-08:30AM

The abstract (#11MO) will be available here on the ELCC 2023 website. The related Mini Oral Presentation with new and updated final data that are not part of the abstract will made available on 31 March 2023 at 08:25AM, CEST and will subsequently be posted on the Posters & Publications section of Immutep’s website.

About Immutep
Immutep is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com

FAQ

What are the key findings of the latest Immutep press release regarding IMMP?

The press release highlighted an 8.3% Overall Response Rate and a 33% Disease Control Rate among NSCLC patients receiving eftilagimod alpha with pembrolizumab.

When will the final data on the TACTI-002 trial be presented?

Final data from Part B of the TACTI-002 trial will be presented at the European Lung Cancer Congress (ELCC) from March 29 to April 1, 2023.

What is the significance of the TACTI-002 trial for IMMP?

The TACTI-002 trial explores treatment options for PD-X refractory NSCLC patients, highlighting Immutep's potential in addressing unmet medical needs.

How many patients were involved in the TACTI-002 Phase II trial?

There were 36 patients involved in Part B of the TACTI-002 Phase II trial.

What does an Overall Response Rate of 8.3% indicate for IMMP's clinical trial?

An Overall Response Rate of 8.3% indicates that while there is some efficacy, the responses may be limited in comparison to other therapies.